Press release
Metastatic Melanoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Metastatic Melanoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Metastatic Melanoma Pipeline Outlook [https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Metastatic Melanoma Pipeline Report
* In January 2025, Melanoma Institute Australia announced a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.
* DelveInsight's Metastatic Melanoma pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Metastatic Melanoma treatment.
* The leading Metastatic Melanoma Companies such as TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others.
* Promising Metastatic Melanoma Pipeline Therapies such as TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others
Stay ahead with the most recent pipeline outlook for Metastatic Melanoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Melanoma Treatment Drugs [https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Melanoma Emerging Drugs
* EVX 01: Evaxion Biotech
EVX-01, is a novel personalized cancer immunotherapy based on Evaxion's proprietary PIONEER Trademark AI technology. EVX-01 is safe and has encouraging early indications of clinically and meaningful antitumor activity. Data showed EVX-01 is capable of eliciting T-cell responses in a clinical setting where the patients received concurrent standard immune therapy, i.e. anti-PD-1 treatment. Results demonstrated an antitumor effect in combination with anti-PD-1 treatment. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.
* IN 10018: InxMed
IN10018 is a potent and highly selective adenosine triphosphate competitive FAK inhibitor, and InxMed has its exclusive global development and commercial operation rights. Early clinical data on IN10018 showed its safety and efficacy in multiple tumor types, and the latest research results and preclinical data demonstrated that IN10018 can also be effective in combination therapies. It is expected to overcome the tumor-associated fibrosis barrier and improve local immunity, and therefore has the potential to act as an important anchor molecule in synergy with different therapeutic modalities including immunotherapy, chemotherapy, and targeted therapy. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.
* AV MEL 1: AiVita Biomedical
AV MEL 1, is an investigational drug being developed by AiVita Biomedical. AIVITA has received IND approval to begin a Phase 1B trial investigating its cancer vaccine in patients with metastatic melanoma plus checkpoint inhibitors.
The Metastatic Melanoma Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Melanoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma Treatment.
* Metastatic Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Melanoma market
Explore groundbreaking therapies and clinical trials in the Metastatic Melanoma Pipeline. Access DelveInsight's detailed report now! @ New Metastatic Melanoma Drugs [https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Melanoma Companies
TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO Internationa LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others.
Unveil the future of Metastatic Melanoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Metastatic Melanoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Metastatic Melanoma Pipeline Report
* Coverage- Global
Metastatic Melanoma Companies- TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO Internationa LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others.
* Metastatic Melanoma Pipeline Therapies- TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others
* Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Metastatic Melanoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Metastatic Melanoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Metastatic Melanoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic Melanoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* EVX 01: Evaxion Biotech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* IN 10018: InxMed
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic Melanoma Key Companies
* Metastatic Melanoma Key Products
* Metastatic Melanoma- Unmet Needs
* Metastatic Melanoma- Market Drivers and Barriers
* Metastatic Melanoma- Future Perspectives and Conclusion
* Metastatic Melanoma Analyst Views
* Metastatic Melanoma Key Companies
* 27. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-melanoma-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Melanoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3966145 • Views: …
More Releases from ABNewswire
5 Starr Heating and Air Shares A Homeowner's Guide Installation Process for HVAC …
Image: https://www.abnewswire.com/upload/2025/10/2ffcb07cb9fcbdae64ba400c1a3a259b.jpg
Deciding to invest in a new heating, ventilation, and air conditioning (HVAC) system is a significant step toward improving the comfort, energy efficiency, and value of your home in Foley, AL. A new system is a promise of reliable relief from our hot, humid summers and cozy warmth during the cooler months. Once you have made the important decision to move forward, the final piece of the puzzle is…
Ralph's Bar & Bowling Introduces Unique Bowling Destination in Catskills, NY
Ralph's Bar & Bowling in the Catskills, NY, offers a unique blend of bowling and bar experiences. With its rustic charm, lively atmosphere, and dedication to quality, the business serves as a community hub and premier entertainment destination for both locals and visitors. This makes it one of the Catskills' most compelling spots for leisure, relaxation, and social connection.
Catskills, NY - Oct 6, 2025 - Ralph's Bar & Bowling [https://www.urbancowboy.com/catskills/ralphs-bar-bowling/]…
Ralph's Bar & Bowling Introduces Signature Cocktail Bar and Wood Fired Pizza in …
Ralph's Bar & Bowling in Big Indian, NY, has introduced a new cocktail bar and gourmet pizza program that builds upon its reputation as a premier dining and entertainment destination in the Catskills. Combining artisanal culinary offerings with handcrafted cocktails, the expansion enhances the venue's role as both a social hub and supporter of local culture. With a refreshed food and beverage program, Ralph's continues to deliver an experience that…
New Analysis Reveals Gold IRA Custodian Fee Structures Differ by Up to 315% Acro …
Independent Research from Gold IRA Blueprint Uncovers Significant Cost Disparities That Could Impact Retirement Savings by Thousands Annually
A comprehensive new analysis from Gold IRA Blueprint reveals dramatic variations in fee structures among leading gold IRA custodians, with total annual costs ranging from zero dollars to over $800 per year - a difference of more than 315% that could significantly impact long-term retirement savings.
The six-month research initiative examined fee structures, storage…
More Releases for Melanoma
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
The Metastatic Melanoma Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Metastatic Melanoma Therapeutics Market Size During the Forecast Period?
The market size for therapeutics in metastatic melanoma has swiftly increased in the past few years. It is projected to augment…
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
What combination of drivers is leading to accelerated growth in the metastatic melanoma therapeutics market?
The growth of the metastatic melanoma therapeutics market is anticipated to be fueled by the increasing prevalence of melanoma cases. Melanoma, a type of skin cancer, originates in the cells, known as melanocytes, that determine the skin's pigment. Melanomas can develop on any part of the skin. Metastatic melanoma therapeutics comprise various treatments designed to interrupt…
Key Influencer in the Melanoma Therapeutics Market 2025: Surge In Melanoma Incid …
How Are the key drivers contributing to the expansion of the melanoma therapeutics market?
The rise in melanoma cases is predicted to fuel the expansion of the melanoma therapeutics market. Melanoma, a type of skin cancer, begins in the melanocytes. The therapies and medications used to treat melanoma patients and mitigate the effects of cancer are known as melanoma therapeutics. An increase in melanoma cases, therefore, leads to a surge in…
Skin Cancer Market By Cancer Type (Melanoma, Non-melanoma)
Most skin cancers are locally destructive malignant growth of the skin. They come from the epidermis cells, the skin's superficial layer. The vast majority of these types of skin cancers seldom spread (metastasize) to other areas of the body and become life-threatening, unlike cutaneous malignant melanoma.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00018117/?utm_source=OpenPR&utm_medium=10379
Key Players Analysis:
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Amgen, Inc.
• Merck & Co., Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Sanofi S.A.
• Qiagen NV
• Sun Pharmaceutical Industries Ltd…
Melanoma Diagnostics Market - Shining Light on Melanoma: Transforming Lives with …
Newark, New Castle, USA - new report, titled Melanoma Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Melanoma Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Melanoma Diagnostics market. The report offers an overview of the market, which…
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic…
